Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹99 | ₹100 |
Expense Ratio | 1.95 | 1.93 |
NAV | ₹34.23 | ₹34.70 |
Fund Started | 11 Jun 2018 | 25 Jun 2018 |
Fund Size | ₹2652.24 Cr | ₹4917.81 Cr |
Exit Load | Exit load of 1% if redeemed within 1 year. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 9.12% | 13.54% |
3 Year | 17.16% | 22.88% |
5 Year | 23.60% | 26.21% |
1 Year
3 Year
5 Year
Equity | 99.83% | 98.79% |
Cash | 0.17% | 1.21% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.82% |
Cipla Ltd. | 7.35% |
Aurobindo Pharma Ltd. | 7.23% |
Lupin Ltd. | 6.32% |
Divi's Laboratories Ltd. | 6.12% |
Glenmark Pharmaceuticals Ltd. | 5.55% |
Apollo Hospitals Enterprise Ltd. | 5.35% |
Dr. Reddy's Laboratories Ltd. | 4.52% |
Krishna Institute of Medical Sciences Ltd | 3.94% |
Suven Pharmaceuticals Ltd. | 3.54% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.56% |
Cipla Ltd. | 9.71% |
Dr. Reddy's Laboratories Ltd. | 8.28% |
Divi's Laboratories Ltd. | 6.05% |
Aurobindo Pharma Ltd. | 4.87% |
Lupin Ltd. | 4.47% |
Alkem Laboratories Ltd. | 3.87% |
Zydus Lifesciences Ltd. | 3.19% |
Gland Pharma Ltd. | 3.19% |
Mankind Pharma Ltd. | 2.81% |
Name | Vrijesh Kasera | Dharmesh Kakkad |
Start Date | 03 Feb 2023 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 11 Jun 2018 | 25 Jun 2018 |
Description
Launch Date